Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined Immunodeficiency

Holly K. Miller, Patrick J. Hanley, Haili Lang, Christopher A. Lazarski, Elizabeth A. Chorvinsky, Sarah McCormack, Lauren Roesch, Shuroug Albihani, Marcus Dean, Fahmida Hoq, Roberta H. Adams, Catherine M. Bollard, Michael D. Keller

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Viral infections can be life threatening in patients with severe combined immunodeficiency (SCID) and other forms of profound primary immunodeficiency disorders both before and after hematopoietic stem cell transplantation (HSCT). Adoptive immunotherapy with virus-specific T cells (VSTs) has been utilized in many patients in the setting of HSCT, but has very rarely been attempted for treatment of viral infections before HSCT. Here we describe the use of VSTs in an infant with RAG1 SCID who had developed disseminated adenovirus which failed to improve on cidofovir. Adenovirus cleared following 2 doses of VSTs and marrow infusion from a matched unrelated donor, without incidence of graft versus host disease. T cell receptor-b sequencing demonstrated expansion of adenovirus-specific T cell fraction of the VSTs, suggesting that infusion facilitated viral clearance. This report suggests that VSTs are likely safe in the pre-HSCT period, and may be a useful bridge therapy for infants with SCID and persistent viral infections.

Original languageEnglish (US)
JournalBiology of Blood and Marrow Transplantation
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Severe Combined Immunodeficiency
Hematopoietic Stem Cell Transplantation
Adenoviridae
Antiviral Agents
Virus Diseases
T-Lymphocytes
Adoptive Immunotherapy
Unrelated Donors
Graft vs Host Disease
Therapeutics
T-Cell Antigen Receptor
Bone Marrow
Viruses
Incidence

Keywords

  • Adenovirus
  • Adoptive immunotherapy
  • Severe combined immunodeficiency
  • T-lymphocytes

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Miller, H. K., Hanley, P. J., Lang, H., Lazarski, C. A., Chorvinsky, E. A., McCormack, S., ... Keller, M. D. (Accepted/In press). Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined Immunodeficiency. Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2018.04.030

Antiviral T Cells for Adenovirus in the Pretransplant Period : A Bridge Therapy for Severe Combined Immunodeficiency. / Miller, Holly K.; Hanley, Patrick J.; Lang, Haili; Lazarski, Christopher A.; Chorvinsky, Elizabeth A.; McCormack, Sarah; Roesch, Lauren; Albihani, Shuroug; Dean, Marcus; Hoq, Fahmida; Adams, Roberta H.; Bollard, Catherine M.; Keller, Michael D.

In: Biology of Blood and Marrow Transplantation, 01.01.2018.

Research output: Contribution to journalArticle

Miller, HK, Hanley, PJ, Lang, H, Lazarski, CA, Chorvinsky, EA, McCormack, S, Roesch, L, Albihani, S, Dean, M, Hoq, F, Adams, RH, Bollard, CM & Keller, MD 2018, 'Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined Immunodeficiency', Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2018.04.030
Miller, Holly K. ; Hanley, Patrick J. ; Lang, Haili ; Lazarski, Christopher A. ; Chorvinsky, Elizabeth A. ; McCormack, Sarah ; Roesch, Lauren ; Albihani, Shuroug ; Dean, Marcus ; Hoq, Fahmida ; Adams, Roberta H. ; Bollard, Catherine M. ; Keller, Michael D. / Antiviral T Cells for Adenovirus in the Pretransplant Period : A Bridge Therapy for Severe Combined Immunodeficiency. In: Biology of Blood and Marrow Transplantation. 2018.
@article{75e4431dce894fe89c45110e30f47327,
title = "Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined Immunodeficiency",
abstract = "Viral infections can be life threatening in patients with severe combined immunodeficiency (SCID) and other forms of profound primary immunodeficiency disorders both before and after hematopoietic stem cell transplantation (HSCT). Adoptive immunotherapy with virus-specific T cells (VSTs) has been utilized in many patients in the setting of HSCT, but has very rarely been attempted for treatment of viral infections before HSCT. Here we describe the use of VSTs in an infant with RAG1 SCID who had developed disseminated adenovirus which failed to improve on cidofovir. Adenovirus cleared following 2 doses of VSTs and marrow infusion from a matched unrelated donor, without incidence of graft versus host disease. T cell receptor-b sequencing demonstrated expansion of adenovirus-specific T cell fraction of the VSTs, suggesting that infusion facilitated viral clearance. This report suggests that VSTs are likely safe in the pre-HSCT period, and may be a useful bridge therapy for infants with SCID and persistent viral infections.",
keywords = "Adenovirus, Adoptive immunotherapy, Severe combined immunodeficiency, T-lymphocytes",
author = "Miller, {Holly K.} and Hanley, {Patrick J.} and Haili Lang and Lazarski, {Christopher A.} and Chorvinsky, {Elizabeth A.} and Sarah McCormack and Lauren Roesch and Shuroug Albihani and Marcus Dean and Fahmida Hoq and Adams, {Roberta H.} and Bollard, {Catherine M.} and Keller, {Michael D.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2018.04.030",
language = "English (US)",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Antiviral T Cells for Adenovirus in the Pretransplant Period

T2 - A Bridge Therapy for Severe Combined Immunodeficiency

AU - Miller, Holly K.

AU - Hanley, Patrick J.

AU - Lang, Haili

AU - Lazarski, Christopher A.

AU - Chorvinsky, Elizabeth A.

AU - McCormack, Sarah

AU - Roesch, Lauren

AU - Albihani, Shuroug

AU - Dean, Marcus

AU - Hoq, Fahmida

AU - Adams, Roberta H.

AU - Bollard, Catherine M.

AU - Keller, Michael D.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Viral infections can be life threatening in patients with severe combined immunodeficiency (SCID) and other forms of profound primary immunodeficiency disorders both before and after hematopoietic stem cell transplantation (HSCT). Adoptive immunotherapy with virus-specific T cells (VSTs) has been utilized in many patients in the setting of HSCT, but has very rarely been attempted for treatment of viral infections before HSCT. Here we describe the use of VSTs in an infant with RAG1 SCID who had developed disseminated adenovirus which failed to improve on cidofovir. Adenovirus cleared following 2 doses of VSTs and marrow infusion from a matched unrelated donor, without incidence of graft versus host disease. T cell receptor-b sequencing demonstrated expansion of adenovirus-specific T cell fraction of the VSTs, suggesting that infusion facilitated viral clearance. This report suggests that VSTs are likely safe in the pre-HSCT period, and may be a useful bridge therapy for infants with SCID and persistent viral infections.

AB - Viral infections can be life threatening in patients with severe combined immunodeficiency (SCID) and other forms of profound primary immunodeficiency disorders both before and after hematopoietic stem cell transplantation (HSCT). Adoptive immunotherapy with virus-specific T cells (VSTs) has been utilized in many patients in the setting of HSCT, but has very rarely been attempted for treatment of viral infections before HSCT. Here we describe the use of VSTs in an infant with RAG1 SCID who had developed disseminated adenovirus which failed to improve on cidofovir. Adenovirus cleared following 2 doses of VSTs and marrow infusion from a matched unrelated donor, without incidence of graft versus host disease. T cell receptor-b sequencing demonstrated expansion of adenovirus-specific T cell fraction of the VSTs, suggesting that infusion facilitated viral clearance. This report suggests that VSTs are likely safe in the pre-HSCT period, and may be a useful bridge therapy for infants with SCID and persistent viral infections.

KW - Adenovirus

KW - Adoptive immunotherapy

KW - Severe combined immunodeficiency

KW - T-lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=85047327444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047327444&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2018.04.030

DO - 10.1016/j.bbmt.2018.04.030

M3 - Article

AN - SCOPUS:85047327444

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -